ARTL Stock Price, Artelo Biosciences Inc Quote, Chart

Market Summary

USD1.39+0.03

Market Closed

2.21%

ARTL Stock Price

View Fullscreen

ARTL RSI Chart

ARTL Valuation

Market Cap

4.5M

Price/Earnings (Trailing)

-0.47

Price/Sales (Trailing)

2.1K

Price/Free Cashflow

-0.5

ARTL Price/Sales (Trailing)

ARTL Profitability

Return on Equity

-100.7%

Return on Assets

-92.76%

Free Cashflow Yield

-199.78%

ARTL Fundamentals

ARTL Revenue

Revenue (TTM)

2.0K

ARTL Earnings

Earnings (TTM)

-9.6M

Earnings Growth (Yr)

-14.53%

Earnings Growth (Qtr)

19.2%

Breaking Down ARTL Revenue

Last 7 days

3.7%

Last 30 days

5.3%

Last 90 days

-16.8%

Trailing 12 Months

-20.6%

How does ARTL drawdown profile look like?

ARTL Financial Health

Current Ratio

11.36

ARTL Investor Care

Shares Dilution (1Y)

13.03%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	3.0K	4.0K	3.0K	2.0K
2021	699.1K	559.7K	420.3K	141.4K
2020	1.3M	1.2M	978.0K	838.6K
2019	735.0K	852.6K	1.2M	1.3M
2018	331.9K	491.8K	585.1K	645.0K
2017	75.4K	98.7K	121.9K	220.1K
2016	0	0	28.9K	52.2K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Artelo Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 12, 2022	gorgas gregory d.	bought	4,800	4.00	1,200	pres, ceo, cfo, treas & secr
Aug 11, 2022	gorgas gregory d.	bought	4,836	4.03	1,200	pres, ceo, cfo, treas & secr
Apr 16, 2021	gorgas gregory d.	bought	9,809	1.154	8,500	pres, ceo, cfo, treas & secr
May 15, 2020	gorgas gregory d.	bought	5,071	1.2076	4,200	pres, ceo, cfo, treas & secr
May 04, 2020	matsui connie	bought	50,000	1.2	41,667	-
May 04, 2020	gorgas gregory d.	bought	5,000	1.2	4,167	pres, ceo, cfo, treas & secr
Nov 04, 2019	gorgas gregory d.	bought	5,303	2.2098	2,400	pres, ceo, cfo, treas & secr
Nov 01, 2019	gorgas gregory d.	bought	5,701	2.2807	2,500	pres, ceo, cfo, treas & secr
Oct 31, 2019	gorgas gregory d.	bought	4,874	1.9499	2,500	pres, ceo, cfo, treas & secr
Oct 30, 2019	gorgas gregory d.	bought	5,186	1.9948	2,600	pres, ceo, cfo, treas & secr

Which funds bought or sold ARTL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Tower Research Capital LLC (TRC)	added	1.35	481	7,205	-%
May 15, 2024	Alpine Global Management, LLC	unchanged	-	-337	226	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	new	-	4.00	4.00	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	2.00	30.00	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	-3.00	3.00	-%
May 14, 2024	Verition Fund Management LLC	unchanged	-	-649	440	-%
May 14, 2024	NewEdge Advisors, LLC	unchanged	-	-	1.00	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	2,179	29,712	-%
May 13, 2024	UBS Group AG	new	-	185	185	-%
May 13, 2024	UBS Group AG	new	-	75.00	75.00	-%

Are Funds Buying or Selling ARTL?

Are funds buying ARTL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ARTL

No. of Funds

Unveiling Artelo Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 23, 2022	iroquois capital management, llc	0.24%	1e+05	SC 13G/A
Feb 09, 2022	parian global management lp	0%	0	SC 13G/A
Feb 04, 2022	hudson bay capital management lp	0%	0	SC 13G/A
Mar 01, 2021	parian global management lp	7.6%	1,199,738	SC 13G
Feb 16, 2021	cvi investments, inc.	4.9%	793,672	SC 13G/A
Feb 10, 2021	bigger capital fund l p	2.8%	450,000	SC 13G/A
Feb 08, 2021	hudson bay capital management lp	5.74%	920,000	SC 13G
Feb 05, 2021	kingsbrook partners lp	4.99%	8e+05	SC 13G/A
Jan 15, 2021	alpha capital anstalt	4.99%	784,008	SC 13G/A
Jan 13, 2021	empery asset management, lp	4.99%	920,000	SC 13G

Recent SEC filings of Artelo Biosciences Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
Mar 29, 2024	S-8	Employee Benefits Plan
Mar 25, 2024	10-K	Annual Report
Mar 04, 2024	8-K	Current Report
Mar 01, 2024	4	Insider Trading
Mar 01, 2024	4	Insider Trading
Mar 01, 2024	4	Insider Trading
Mar 01, 2024	4	Insider Trading
Mar 01, 2024	4	Insider Trading
Mar 01, 2024	4	Insider Trading

Peers (Alternatives to Artelo Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Artelo Biosciences Inc News

Latest updates

Artelo Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-	-	-	-	1.00	1.00	1.00	1.00	76.00	151	226	198	195	193	304	215	266	433	354	210	167	121
Operating Expenses	-6.8%	3,240	3,476	2,394	2,471	1,946	4,042	2,552	2,245	1,517	2,251	1,868	1,436	1,028	951	1,371	1,336	953	-	-	-	-
S&GA Expenses	-36.2%	1,116	1,750	1,316	1,415	1,482	2,098	1,279	1,211	697	1,074	1,006	841	1,541	389	434	403	286	403	-	-	-
R&D Expenses	23.1%	2,124	1,726	1,078	1,056	464	1,944	1,273	1,034	933	951	663	595	272	259	721	667	234	-	-	-	-
Interest Expenses	-	-	-	5.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	8.0%	-3,073	-3,339	-2,330	-2,449	-1,965	-4,035	-2,548	-2,245	-1,517	-2,249	-1,865	-1,435	-1,027	-951	-1,370	-1,306	-845	-	-	-	-
Net Income Margin	7.9%	-4.64	-5.04	-3.59	-2.75	-3.60	-5.17	-60.54*	-29.43*	-18.36*	-14.07*	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-13.2%	-2,596	-2,293	-1,696	-1,966	-2,053	-2,667	-1,926	-1,055	-1,055	-1,742	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Assets	-20.6%	10,354	13,043	15,499	16,877	18,478	20,424	22,415	24,405	26,704	28,251	29,004	12,635	12,340	13,445	9,539	4,376	3,494	4,152	5,548	6,483	1,153
Current Assets	-25.4%	8,188	10,980	13,428	14,602	16,386	18,322	20,303	22,282	24,589	24,609	25,355	10,317	10,300	11,405	7,500	2,337	1,453	2,111	3,508	4,443	1,152
Cash Equivalents	-57.5%	1,195	2,815	2,639	5,719	6,916	6,888	7,136	12,122	10,350	12,162	14,047	6,629	10,052	10,706	7,389	2,142	1,279	1,983	3,375	4,424	-
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	63*	124*	185*	246*	1.00	2.00	598*	721*	857*
Liabilities	-36.7%	817	1,291	921	609	840	1,021	512	567	924	1,084	718	593	570	547	524	501	-	-	-	-	-
Current Liabilities	-44.2%	721	1,291	921	603	825	998	480	527	875	1,027	659	526	424	589	486	501	268	444	585	1,022	1,019
Shareholder's Equity	-18.8%	9,537	11,752	14,578	16,268	17,638	19,403	21,903	23,838	25,780	27,167	28,286	12,042	11,916	12,856	9,054	3,875	3,225	3,708	4,963	5,460	-
Retained Earnings	-6.2%	-42,793	-40,310	-37,237	-34,788	-33,189	-31,021	-27,682	-25,352	-22,903	-20,938	-19,451	-16,903	-15,015	-12,766	-10,900	-9,466	-8,438	-7,487	-6,117	-4,810	-3,965
Additional Paid-In Capital	0.5%	52,530	52,262	52,011	51,254	51,029	50,675	49,970	49,324	48,705	48,120	47,718	28,925	26,859	25,552	19,891	13,272	11,609	11,176	11,071	10,278	4,108
Accumulated Depreciation	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00	2.00	1.00	1.00	1.00	1.00	886*	792*	646*
Shares Outstanding	1.2%	3,228	3,189	3,162	2,856	2,856	2,856	2,856	2,840	2,820	2,820	2,820	1,635	1,543	1,481	-	-	-	-	-	-	-
Float	-	-	-	-	5,630	-	-	-	13,685	-	-	-	-	-	39,891	-	-	-	2,970	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q3	2021Q2	2021Q2	2021Q1	2021Q1	2020Q4	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-13.3%	-2,942	-2,596	-1,802	-1,623	-2,186	-2,293	-1,696	-1,966	-2,053	-2,667	-1,926	-	-1,055	-	-	-1,742	-945	-1,874	-1,320	-872	-1,020
Share Based Compensation	-2.7%	213	219	222	225	354	608	607	619	624	934	571	502	-	609	-	519	323	70.00	51.00	55.00	53.00
Cashflow From Investing	-53.7%	1,269	2,741	-1,832	399	2,199	1,796	-3,080	3,985	257	-10,033	-8,878	-	-	-1,289	-	-2,044	544	-1,055	-	1.00	-
Cashflow From Financing	71.9%	55.00	32.00	535	-	-	134	-	-134	-	18,261	18,262	-	890	-	-	6,009	5,320	6,578	6,579	1,710	283

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ARTL Income Statement

2024-03-31

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
OPERATING EXPENSES
General and administrative	$ 1,082	$ 1,057
Research and development	1,507	1,235
Total Operating Expenses	2,589	2,292
Loss from Operations	(2,589)	(2,292)
OTHER INCOME
Net change in fair value of trading marketable securities	106	124
Total other income	106	124
Provision for income taxes	0	0
NET LOSS	(2,483)	(2,168)
OTHER COMPREHENSIVE INCOME
Unrealized gain on available-for-sale securities	0	29
Foreign currency translation adjustments	0	20
Total Other Comprehensive Income	0	49
TOTAL COMPREHENSIVE LOSS	$ (2,483)	$ (2,119)
Basic and Diluted Loss per Common Share	$ (0.78)	$ (0.76)
Basic and Diluted Weighted Average Common Shares Outstanding	3,197	2,856

ARTL Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 1,195	$ 2,815
Trading marketable securities	6,414	7,611
Prepaid expenses and other current assets	579	554
Total Current Assets	8,188	10,980
Operating lease right-of-use assets	124	21
Intangible asset	2,039	2,039
Other assets	3	3
TOTAL ASSETS	10,354	13,043
Current Liabilities
Accounts payable and accrued liabilities	607	1,238
Due to related parties	83	30
Operating lease liabilities - current portion	31	23
Total Current Liabilities	721	1,291
Operating lease liabilities	96	0
TOTAL LIABILITIES	817	1,291
STOCKHOLDERS' EQUITY
Preferred Stock, par value $0.001, 416,667 shares authorized, 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common Stock, par value $0.001, 50,000,000 shares authorized, as of March 31, 2024 and December 31, 2023 3,227,700 and 3,188,959 shares issued and outstanding as of March 31, 2024 and December 31, 2023	3	3
Additional paid-in capital	52,530	52,262
Accumulated deficit	(42,793)	(40,310)
Accumulated other comprehensive loss	(203)	(203)
TOTAL STOCKHOLDERS' EQUITY	9,537	11,752
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 10,354	$ 13,043

About Artelo Biosciences Inc

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

CEO	Mr. Gregory D. Gorgas M.B.A.
WEBSITE	artelobio.com
INDUSTRY	Biotechnology
EMPLOYEES	5

Artelo Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Artelo Biosciences Inc? What does ARTL stand for in stocks?

ARTL is the stock ticker symbol of Artelo Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Artelo Biosciences Inc (ARTL)?

As of Fri May 17 2024, market cap of Artelo Biosciences Inc is 4.49 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARTL stock?

You can check ARTL's fair value in chart for subscribers.

What is the fair value of ARTL stock?

You can check ARTL's fair value in chart for subscribers. The fair value of Artelo Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Artelo Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARTL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Artelo Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether ARTL is over valued or under valued. Whether Artelo Biosciences Inc is cheap or expensive depends on the assumptions which impact Artelo Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARTL.

What is Artelo Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ARTL's PE ratio (Price to Earnings) is -0.47 and Price to Sales (PS) ratio is 2.1 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARTL PE ratio will change depending on the future growth rate expectations of investors.